Since adenosine is an important immunosuppressive metabolite in the tumor microenvironment, strategies targeting the adenosine pathway and its related targets have attracted increasing attention in tumor immunology in recent years, and CD73 is one of the most concerned targets (6–8). This evidence concerns the gene NT5E and neoplasm.